As the new year begins, we are looking ahead to four key megatrends that we expect to shape the landscape in the year to come.
About Sam BarnumThis author has not yet filled in any details.
So far Sam Barnum has created 29 blog entries.
As a result of Brexit, the In Vitro Diagnostic Medical Device Regulations (IVDR) will not apply to Great Britain. Unlike Great Britain, the IVDR will apply in Northern Ireland from 26 May 2022.
BHA Partners with Alcon to Conduct Real-World Study Highlighting Efficiencies of Optical Biometer in Cataract SurgerySam Barnum2020-12-15T16:09:39-05:00
Alcon, a global leader in eye care, collaborated with Boston Healthcare to conduct a Time-and-Motion Study to support the value communication of its novel swept-source optical coherence tomography biometer, ARGOS®.
In November 2020, two years following the implementation of the national centralized tender program that started with biopharmaceuticals, the first medical device was targeted - drug-eluting coronary stents.
The pilot of implementing a diagnosis-related group (DRG) payment model to inpatient hospital care, a major initiative of China’s ongoing healthcare reform, started in 2019. Boston Healthcare Associates has been vigilant in tracking this strategic topic given the implications on the industry and the healthcare ecosystem as a whole.
Eight leaders in Life Sciences came together for a virtual breakfast roundtable devoted to leading Life Sciences organizations through these unprecedented times.
CMS Proposes Changes to Part B Medicare Reimbursement for Physician-Administered Drugs Approved Under the 505(b)(2) Approval PathwaySam Barnum2020-11-02T11:46:40-05:00
The Centers for Medicare and Medicaid Services (CMS) intends to alter assignment of Healthcare Common Procedure Coding System (HCPCS) Level II codes for certain physician-administered 505(b)(2) drugs.
Recently, Medicare published two CRs associated with the NGS NCD, identifying covered tests and associated CPT and ICD-10 diagnosis codes. These CRs (CR11655 and CR11749) indicated that MSK-IMPACT and MyMRD NGS Panel were nationally covered under the NGS NCD.
G-BA Specifies Procedures for Coverage with Evidence Development- Gene Therapy Zolgensma® First CaseSam Barnum2020-08-04T14:31:15-04:00
In Germany, the Federal Joint Committee (G-BA) recently amended its rules of assessment procedures to consider new therapies and products without complete clinical data at the time of approval.
The National Health Commission of China recently released a clinical practice to regulate physician prescribing behavior for novel cancer therapies which echoes the government's efforts to control costs.